All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group

Covid-19 vaccine developer BioNTech attracts Temasek investment


German biotechnology company BioNTech has raised $225m via a private placement led by Singaporean sovereign wealth fund Temasek, amid growing investor appetite for biotech investments due to the Covid-19 pandemic.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree